Select Page

Our Business

As one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.

Millions of people around the world are affected by multiple sclerosis (MS), Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).

Our portfolio of therapies provides treatment for diseases that are among humanity’s most complex and difficult health challenges. Our strategy is focused on strengthening the Biogen of today, while at the same time preparing for the Biogen of tomorrow. To leverage a strong core business that helps drive future growth, our five strategic priorities focus on existing offerings and developing new value:

  • Maximizing the resilience of our core MS business to drive earnings and cash flow
  • Accelerating efforts in SMA to shift towards new growth opportunities
  • Developing and expanding our neuroscience portfolio to create the future growth engines of Biogen
  • Re-prioritizing our capital allocation efforts to continue to maximize shareholder value, with an increased focus on investment for future growth
  • Creating a leaner and simpler operating model

As we work to defeat neurological diseases, we must hold ourselves accountable to deliver value to our shareholders and continue to commit to maintaining professional, ethical and compliant behavior every day. At the same time, we are stewards of our community and environment. We are responsible corporate citizens, working to create positive impacts on society, the environment, our employees’ lives and our communities – and working to get our products to those who need them around the globe.

  Our Business

As one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.

Millions of people around the world are affected by multiple sclerosis (MS), Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).

Our portfolio of therapies provides treatment for diseases that are among humanity’s most complex and difficult health challenges. Our strategy is focused on strengthening the Biogen of today, while at the same time preparing for the Biogen of tomorrow. To leverage a strong core business that helps drive future growth, our five strategic priorities focus on existing offerings and developing new value:

  • Maximizing the resilience of our core MS business to drive earnings and cash flow
  • Accelerating efforts in SMA to shift towards new growth opportunities
  • Developing and expanding our neuroscience portfolio to create the future growth engines of Biogen
  • Re-prioritizing our capital allocation efforts to continue to maximize shareholder value, with an increased focus on investment for future growth
  • Creating a leaner and simpler operating model

As we work to defeat neurological diseases, we must hold ourselves accountable to deliver value to our shareholders and continue to commit to maintaining professional, ethical and compliant behavior every day. At the same time, we are stewards of our community and environment. We are responsible corporate citizens, working to create positive impacts on society, the environment, our employees’ lives and our communities – and working to get our products to those who need them around the globe.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat MS, has introduced the first and only approved treatment for SMA and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

Biogen is proud to employ 7,000+ people around the world who share a singular focus: to make a meaningful difference in the lives of people suffering from devastating neurological conditions.

We ground our business, and our commitment to diversity and inclusion, in the steadfast belief that humanity benefits when employees can bring their whole selves to work and contribute to their fullest potential. Our continued pursuit of scientific and therapeutic excellence is powered by the talent and commitment of our people.

Our Business Highlights

$12.3B

(US Dollars) in revenue in 2017

7,000+

employees worldwide

1st

and only approved treatment for spinal muscular atrophy (SMA)

36%

of MS patients worldwide treated with Biogen products¹

3

anti-TNF biosimilars approved in the European Union²

>$2B

spent on R&D in 2017 alone

~20%

of annual revenues invested into R&D over the past decade

>130

active studies³

5

pipeline candidates transitioned from research to development, nearly doubling our historical productivity in 2017

7

new clinical stage programs across our core and emerging growth areas were added in 2017

$12.3B

(US Dollars) in revenue in 2017

7,000+

employees worldwide

1st

and only approved treatment for spinal muscular atrophy (SMA)

36%

of MS patients treated with our medicines globally¹

3

anti-TNF biosimilars approved in the EU²

>$2B

spent on R&D in 2017 alone

~20%

of annual revenues invested into R&D over the past decade

>130

active studies³

5

pipeline candidates transitioned from research to development, nearly doubling our historical productivity in 2017

7

new clinical stage programs across our core and emerging growth areas were added in 2017

Our Business Highlights

$12.3B

(US Dollars) in revenue in 2017

3

anti-TNF biosimilars approved in the European Union²

5

pipeline candidates transitioned from research to development, nearly doubling our historical productivity in 2017

7,000+

employees worldwide

~20%

of annual revenues invested into R&D over the past decade

7

new clinical stage programs across our core and emerging growth areas were added in 2017

1st

and only approved treatment for spinal muscular atrophy (SMA)

$>2B

spent on R&D in 2017 alone

36%

of MS patients worldwide treated with Biogen products¹

>130

active studies³

Research & Development and Pipeline

We believe we are at the forefront of a transformative era of neuroscience drug discovery and development. As a pioneer in biotechnology, we have one overarching focus: developing novel medicines that can improve the lives of people living with devastating neurological and neurodegenerative diseases. We measure our success by the impact we have on individuals living with these diseases, families and caregivers. Every day, we ask ourselves one essential question: How can we best make a difference in people’s lives?

We believe that our history and commitment to addressing complex neurological conditions gives us a competitive advantage with our strategic approach to research and development. The successful SPINRAZA launch exemplifies our ability to bring new therapies to patients in need. Our goal is to leverage our leadership and experience in neurology to target our efforts to the areas of greatest need and opportunity and to advance a world-class neuroscience R&D program.

Neuroscience is vast with many intersecting disciplines. To drive results and maintain our strong leadership position in the development of the therapies of tomorrow, our strategy is to focus on four core and four emerging growth areas.

Core Growth Areas

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our core growth areas include: MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders and neuromuscular disorders. We engage with physicians and scientific leaders around the world with the aim to further medical research. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines with the aim of transforming neuroscience to benefit society.

Emerging Growth Areas

Biogen has some of the world’s best neurologists and neuroscientists working to create the therapies of tomorrow and expanding our understanding of the basic science behind some of the most complex neurological conditions. At the same time, we engage with physicians and scientific leaders around the world to further medical research in other areas that complement our core growth areas. Biogen’s emerging growth areas – which include pain, ophthalmology, neuropsychiatry and acute neurology – follow from our expertise in our core growth areas.

Platforms and Modalities

Through the use of our core platforms and modalities, Biogen is working to bring new scientific understanding to diseases for which there are no adequate treatments. These research platforms are built to support key drug modalities used at Biogen.     Our core research platforms are designed to predict drug concentrations in blood and tissues using physiologic based pharmacokinetic modeling approaches and linking these concentrations to drug effects using biomarker, imaging, safety and clinical endpoints. Biogen discovers and develops therapeutics in multiple drug modalities, including small molecules, biologics, antisense oligonucleotides and gene therapy. Learn more about the diseases we’re focused on and the therapies in our pipeline.

2017 Financial Highlights

$12.3B

revenues (US Dollars)

$2.7B

net income

$11.92

diluted earnings per share⁴

$12.6B

shareholders’ equity

$1.1B

income tax payments, net

$6.2M

philanthropic giving

$12.3B

revenues (US Dollars)

$2.7B

net income

$11.92

diluted earnings per share⁴

$1.1B

income tax payments, net

$6.2M

philanthropic giving

$12.6B

shareholders’ equity

$12.3B

revenues (US Dollars)

$6.2M

philanthropic giving

$2.7B

net income

$12.6B

shareholders’ equity

$11.92

diluted earnings per share⁴

$1.1B

income tax payments, net

Footnotes:

  1. Biogen data on file.
  2. Two currently available for treatment; a third has been granted marketing authorization by the European Commission and is expected to launch in Europe in October 2018.
  3. Active study includes all studies between pre-Study Management Team (SMT) formation and Clinical Study Report (CSR) as defined by internal systems as of April 23, 2018.
  4. “Diluted Earnings Per Share” for 2017 reflects the impact of the Tax Cuts and Jobs Act of 2017 and higher costs associated with our external business development activities, including our agreements with Bristol-Myers Squibb Company, Ionis Pharmaceuticals Inc., Neurimmune Subone AG and Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc.